Livzon Pharmaceutical Group Inc. (Livzon Pharma) filed its Monthly Return on Movements in Securities for the period ended 31 March 2026, showing no change in either authorised or issued share capital.

• Authorised/Registered Capital – H shares: 299.81 million shares at RMB 1 par value. – A shares: 588.10 million shares at RMB 1 par value. – Combined total: 887.91 million shares, unchanged from the previous month.

• Issued Shares and Treasury Position – H shares in issue: 299.81 million; treasury shares: 0. – A shares in issue: 588.10 million; treasury shares: 0. – No issuance, cancellation, or repurchase activity occurred during the month.

• Public Float – The company confirmed compliance with the Hong Kong Stock Exchange’s minimum public-float requirement of 5% for its H-share class as of 31 March 2026.

• Capital Instruments and Corporate Actions – The filing reports no outstanding share options, warrants, convertible securities, HDRs, or other equity-linked instruments.

The March 2026 return indicates a stable capital structure, with Livzon Pharma maintaining both its share count and full adherence to listing rule obligations.